This study is currently not recruiting participants.

A Phase 2 Multicenter Randomized Parallel-Arm Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn's Disease (SERENITY)

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to determine whether LY3074828, a humanized immunoglobulin G4 (IgGa)-variant monoclonal antibody that is directed against the p19 subunit of interleukin 23 (IL-23), is safe and efficacious in subjects with moderate to severe Crohn's disease.

Description

The purpose of this study is to determine whether LY3074828, a humanized immunoglobulin G4 (IgGa)-variant monoclonal antibody that is directed against the p19 subunit of interleukin 23 (IL-23), is safe and efficacious in subjects with moderate to severe Crohn's disease.

Details
Condition Crohn's disease
Age 100years or below
Clinical Study IdentifierTX7658
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.